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Beta-Thalassemia Disease
Rungrote Natesirinilkul
Abstract
Thalassemia disease is a common inherited hemolytic anemia frequently found 
in several parts of the world, especially in the Mediterranean and some Asian 
countries. Besides the complications of secondary hemochromatosis from regular 
red blood cell (RBC) transfusion and increased gastrointestinal absorption of 
iron, thromboembolism (TE) is one of the common long-term complications of 
beta-thalassemia disease, particularly in patients with non-transfusion-dependent 
thalassemia (NTDT), which is commonly seen after the second decade of life. The 
risk factors of TE in beta-thalassemia disease including exposure of phosphatidyl-
serine of abnormal RBCs, increase of platelet activation and aggregation, elevation 
of endothelial microparticles and increased endothelial activation, decreased nitric 
oxide (NO) secondary to hemolysis, rise of platelet count and nucleated RBCs after 
splenectomy, organ dysfunction caused by hemochromatosis, and thrombophilia 
such as natural anticoagulant deficiencies leading to hypercoagulable state. The 
understanding of the pathophysiology would result in effective prevention of this 
complication of beta-thalassemia disease.
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1. Introduction
Beta-thalassemia disease is one of the most common congenital hemolytic 
anemia commonly found in the malarial belt areas including the Mediterranean, 
the Middle East, Transcaucasus, Africa, South and Southeast Asian countries, and 
China [1]. It is inherited by autosomal recessive manner [1, 2]. Beta-thalassemia 
disease is the result from the mutation of beta-globin genes causing decrease of 
beta-globin leading to imbalance of alpha-globin and beta-globin and subsequently 
causing ineffective erythropoiesis. According to the Thalassemia International 
Federation (TIF), patients with thalassemia disease can be categorized into two 
groups, transfusion-dependent thalassemia (TDT) and non-transfusion-dependent 
thalassemia (NTDT), based on their phenotypes and genotypes [1–3]. The major 
long-term complication of TDT is hemochromatosis-induced organ failures second-
ary to red blood cell (RBC) transfusion [1, 2], while the complications of NTDT 
are hemochromatosis secondary to increased iron absorption from gastrointestinal 
tract, pulmonary hypertension, leg ulcer, and thromboembolism (TE) [3–5].
The incidence of thromboembolism is between 0.8 and 2.7 per 1000 population 
[6] which has been increasing over the decades in both adult and pediatric popula-
tion [6, 7] patients with thalassemia disease are at risk of hypercoagulable state and 
thromboembolism [8, 9]. The studies of thromboembolism in thalassemia disease 
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have been increasingly published recently. Understanding the pathophysiology of 
thromboembolism in thalassemia diseases is the key for the management to prevent 
this complication.
2. Incidence
The incidence of thromboembolism in patients with thalassemia diseases is 
between 1.7 and 9.2% [4, 10, 11]; therefore, the incidence of thromboembolism in 
patients with thalassemia diseases is approximately 10 times higher than normal 
population [6]. The incidence is 4.4 times more prevalent in patients with NTDT 
than ones with TDT [10]. However, this complication could be seen in both patients 
alpha- and beta-thalassemia diseases [4].
3. Pathophysiology
The pathophysiology of thromboembolism in beta-thalassemia disease is the 
combinations of abnormalities in several parts of hemostatic system including [9, 12]:
1. Exposure of phosphatidylserine (PS) to external membrane of abnormal RBCs 
called “flip-flop phenomenon” which is caused by the decrease of normal 
asymmetrical dissemination of RBC membrane phospholipids [9]. In addition, 
free iron secondary to hemochromatosis induces lipid oxidation and elevates 
the level of membrane-bounded hemichromes and immunoglobulin causing 
alteration of the structures of spectrin and band 3 protein of RBC membrane 
and consequently resulting in aggregation and adhesion of abnormal RBCs to 
endothelial cells [9].
2. Increased number of circulating activated and aggregated platelets which 
are especially found in splenectomized patients [13, 14]. The activated and 
aggregated platelets of splenectomized patients with thalassemia usually have 
shorter platelet lifespan [14], higher response to several agonists, i.e., adeno-
sine diphosphate (ADP), epinephrine, and collagen [15], and more elevated 
level of plasma beta-thromboglobulin [16] than the platelets of normal 
population. All findings reflect hyperaggregation of platelets which result in 
increased thrombin generation [15].
3. Increased endothelial activation caused by the activation of monocytes and 
granulocytes leads to endothelial injury and increased level of endothelial 
adhesion proteins and tissue factor contributing to hypercoaguable state. 
Moreover, the elevation of endothelial cell, platelet and white blood cell 
(WBC) and RBC microparticles, which are the shedded fragments containing 
high PS with the size of 0.1–2 μm from activated and apoptotic cells, leads to 
increased activation of hemostatic system [17–19].
4. Decreased nitric oxide (NO), secondary to hemolysis caused by the decreased 
level of arginine leads to pulmonary vasoconstriction and subsequently results 
in chronic pulmonary thromboembolism [12, 20].
5. Rise of platelet count and nucleated RBCs (NRBCs) after splenectomy which 
was firstly reported in 1966 [21]. This phenomenon is a strong associated 
factor of thromboembolism in patients with thalassemia disease particularly 
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when the platelet count is higher than 600,000/mm3 and the NRBCs count is 
more than 300/mm3 after splenectomy [22].
6. Organ dysfunction resulting from hemochromatosis particularly cardiac 
hemochromatosis causes cardiomyopathy and cardiac arrhythmia [12] which is 
found in beta-thalassemic patients who TDT for 42% [23].
7. Thrombophilia, i.e., natural anticoagulant deficiencies, leads to hyperco-
agulable state. Deficiencies of protein C and protein S, the natural antico-
agulant proteins, have been reported as a risk factor of thromboembolism 
in patients with beta-thalassemia disease [12, 24, 25]. In addition, increased 
incidence of antiphospholipid antibodies, i.e., lupus anticoagulant, anti-
cardiolipin, and anti-beta 2-glycoprotein 1, is commonly found in patients 
with beta-thalassemia disease. Those antibodies are considered as strong 
thrombophilic risk factors causing thromboembolism [12, 26].
4 Presentations of thromboembolism in beta-thalassemia
Thromboembolism in patients with beta-thalassemia diseases could be found in 
both arterial and venous sites. However, venous thromboembolism is more com-
monly found in patients with thalassemia intermedia or NTDT, while arterial throm-
boembolism is more frequently seen in patients with thalassemia major or TDT [10].
4.1 Venous thromboembolism
Although patients with beta-thalassemia disease are at risk of venous throm-
boembolism, deep vein thrombosis and pulmonary thromboembolism, the two 
common types of venous thromboembolism in normal population, are not generally 
observed. Pulmonary thromboembolism was found in lung biopsy to 41% of patients 
with beta-thalassemia/hemoglobin E. However, higher incidence was found in the 
older and splenectomized patients [27]. Simplified, revised Geneva score, based on 
several clinical variables, i.e., hemoptysis, old age of more than 65 years, history of 
venous thromboembolism, tachycardia, unilateral lower limb pain with or without 
deep palpation and edema, active malignancy, and surgery or fracture of lower limb 
within 1 month prior to the suspected symptoms and signs, has been published to 
use for diagnosing pulmonary thromboembolism. The more scores patients get, the 
higher chance of pulmonary embolism patients have [28]. Computed tomography 
pulmonary angiography, magnetic resonance pulmonary angiography, and ventila-
tion/perfusion scan could be used to diagnose pulmonary thromboembolism even 
though conventional pulmonary angiography is the gold standard [29].
Portal vein thrombosis, which is considered as venous thrombosis of an unusual 
site, is more commonly reported in patients with beta-thalassemia disease [30–34] 
with the odds ratio of 3.5 [31]. Patients with acute portal vein thrombosis usually 
present with symptoms and signs of portal hypertension of bowel ischemia, i.e., 
abdominal pain and distension, fever, nausea/vomiting, rectal hemorrhage, and 
splenomegaly. If patients were not diagnosed, they might turn to sepsis-like symp-
toms, e.g., shock, signs of peritonitis, and even death [35]. Unlike acute portal vein 
thrombosis, patients with chronic portal vein thrombosis are usually asymptomatic 
until the presence of first symptoms and signs, i.e., upper gastrointestinal hemor-
rhage, splenomegaly, and ascites [35]. Doppler ultrasound, computed tomogra-
phy, and magnetic resonance imaging could be used for diagnosis of portal vein 
thrombosis [35]. Apart from splenectomy, higher splenic weight and thalassemia 
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intermedia are major risk factors of portal vein thrombosis in patients with beta-
thalassemia disease [30, 33]. Laparoscopic splenectomy was reported about the 
higher incidence of portal vein thrombosis even though this technique provided the 
better other surgical outcomes than the conventional technique [30].
4.2 Arterial ischemic stroke
Beta-thalassemia disease has been reported as a risk factor of arterial ischemic 
stroke since 1972 [36]. Compared to venous thromboembolism, arterial ischemic 
stroke is more common in patients with beta-thalassemia major [11]. Moyamoya 
syndrome, a cerebral vasculopathy caused by spontaneous occlusion of the arter-
ies at the circle of Willis [37], was also reported in pediatric patients with beta-
thalassemia disease and caused arterial ischemic stroke [38, 39]. Symptom and 
signs of acute ischemic stroke are based on the involved cerebral areas ranging from 
nonspecific symptoms, i.e., headache, nausea and vomiting, seizure, and impaired 
consciousness to specific neurological deficits, i.e., abnormal speech and spatial 
perception, hemiparesis, hemianesthesia, blurred vision, and poor coordination or 
walking, and cranial nerve palsies [40]. Though computed tomography of the head 
with or without angiography is the standard for diagnosing arterial ischemic stroke, 
magnetic resonance imaging of head with or without angiography could provide 
more details of the affected parts of the brain with higher sensitivity [40].
Moreover, the focal foci in the cerebral white matter on the magnetic resonance 
imaging of the brain called “silent cerebral infarction” could be found at 24–61% 
of patients with beta-thalassemia disease [41, 42]. However, a recent study in adult 
patients with beta-thalassemia disease who were asymptomatic showed that the 
abnormal findings on the magnetic resonance imaging of the brain were not differ-
ent from the adult controls [43].
4.3 Diagnosis
Making a diagnosis of thromboembolism in patients with beta-thalassemia does 
not differ from diagnosing this condition in normal population which is usually 
based on the imaging of the suspected area of thromboembolism, e.g., computed 
tomography with angiography of the brain in a patient who is suspicious for hav-
ing an arterial ischemic stroke. Several studies have demonstrated derangement 
of proteins hemostatic system in patients with beta-thalassemia diseases includ-
ing increased platelet aggregation and coagulation proteins (factor VIII and von 
Willebrand factor) and decreased natural anticoagulants (protein C, protein S, and 
antithrombin) [24, 25] which encourage hypercoagulable state [44]. Besides diagnos-
ing a symptomatic patient, the novel investigations, i.e., thrombin generation assay 
and rotatory thromboelastometry (ROTEM®), are able to demonstrate patients with 
hypercoagulable state in patients with beta-thalassemia disease who are at risk of 
developing thromboembolism [45, 46]. In addition, yearly monitoring of thrombin 
generation markers, e.g., D-dimer and thrombin-antithrombin (TAT) complex, is 
recommended by TIF in patients with thalassemia who are splenectomized [47].
5. Treatment
1. Regular RBC transfusion is recommended to treat patients with beta- 
thalassemia disease, particularly NTDT, who are at risk of thromboembolism 
or have developed thromboembolic events by keeping hemoglobin level higher 
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than 9 g/dL [3] to correct hypercoagulable state as transfusion naïve patients 
are prone to have thromboembolism [12, 22, 48].
2. Hematopoietic stem cell transplantation (HSCT) has been reported as the 
management that could normalize the abnormal hemostatic derangement in 
patients with beta-thalassemia disease by increasing natural anticoagulant 
proteins and decreasing microparticles and RBC-expressing PS and activating 
platelets in the circulation [49, 50].
3. Antithrombotic agents in patients with beta-thalassemia disease who have 
thromboembolism are recommended as per the standard local or international 
guidelines to treat patients with thromboembolism [3, 12]
a. Anti-platelets: acetyl salicylic acid (ASA)
ASA 2–5 mg/kg/day is the mainstream management for the prevention and 
treatment of thromboembolism in patients in beta-thalassemia especially in 
splenectomized patients who have platelet count higher than 500,000/mm3 [3]. 
However, ASA resistance has been reported in patients with thalassemia who were 
splenectomized, and increase dose of ASA could overcome this resistance [51].
b. Anticoagulants consist of conventional anticoagulants, i.e., unfractionated 
heparin, low-molecular-weight heparin, vitamin K antagonist (VKA), and 
direct oral anticoagulants (DOAC) including direct oral anti-activated fac-
tor X (Xa), e.g., rivaroxaban, and direct oral antithrombin (IIa), i.e. dabi-
gratan. Those medications are used to treat thromboembolism in patients 
with beta-thalassemia disease. Unlike sickle cell disease, the evidences of 
using DOAC in patients with thalassemia disease who develop thrombo-
embolism are limited [52]. However, the recent study showed that using 
rivaroxaban in patients with hemoglobinopathies including thalassemia 
was effective and did not increase risk of bleeding or thrombosis [53].
4. Hydroxyurea, a hemoglobin F stimulating agent, was reported about the 
favorable effects not only increased hemoglobin F, hemoglobin level and 
improved the clinical symptoms of beta-thalassemia disease but also decreased 
hypercoagulable state due to the diminished exposure of PS on RBC membrane 
[54, 55]. Moreover, Iqbal et al. recently reported the change of metabolites, 
i.e., glycerol, triethanolamine, linoleic acid, palmitic acid, and stearic acid 
to the healthy pattern of metabolic pathway in pediatric patients with beta-
thalassemia disease after treating with hydroxyurea [56].
Since patients with beta-thalassemia disease are at risk of thromboembolism 
as the same as other medical inpatients, the current approach is to stratify patients 
with the optimal risk assessment model (RAM) by using the available approaches, 
e.g., Padua Prediction Score and the Caprini Risk Assessment Model, to guide 
thromboprophylaxis [57]. However, the systematic review showed that there 
was not any specific risk assessment model which was superior to the others [58]. 
Moreover, thalassemia-specific risk assessment model for thromboprophylaxis may 
need to be developed due to distinctive pathophysiology of thromboembolism in 
patients with beta-thalassemia disease.
In conclusion, the hypercoagulable state in beta-thalassemia disease is the 
result of several risk factors, a combination of which is often the drive behind a 
clinical thromboembolism. Splenectomy and transfusion naivety are increasingly 
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highlighted as important risk factors for thromboembolism, especially in patients 
with NTDT. An individualized approach is recommended to establish an optimal 
strategy for preventing the occurrence of this complication in patients with beta-
thalassemia disease.
© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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